Linaclotide: a novel approach to the treatment of irritable bowel syndrome.

about

Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome.Drug development for the irritable bowel syndrome: current challenges and future perspectives The safety of novel drugs used to treat irritable bowel syndrome.

P2860

Q33454969-957BA328-3BEC-4F10-B694-ABB58E5751DD Q36579818-4DFAFD20-149B-4971-9E52-D6D8486AA695 Q38199522-D73F2A9C-9330-48B0-9E19-5D7C9C71EC12

P2860

Linaclotide: a novel approach to the treatment of irritable bowel syndrome.

Item

http://www.wikidata.org/entity/Q37951907

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Linaclotide: a novel approach to the treatment of irritable bowel syndrome.

@en

Linaclotide: a novel approach to the treatment of irritable bowel syndrome.

@nl

type

Item

label

Linaclotide: a novel approach to the treatment of irritable bowel syndrome.

@en

Linaclotide: a novel approach to the treatment of irritable bowel syndrome.

@nl

prefLabel

Linaclotide: a novel approach to the treatment of irritable bowel syndrome.

@en

Linaclotide: a novel approach to the treatment of irritable bowel syndrome.

@nl

P1476

Linaclotide: a novel approach to the treatment of irritable bowel syndrome.

@en

P2093

David R Luthin

http://www.w3.org/2001/XMLSchema#string

Terri M Wensel

http://www.w3.org/2001/XMLSchema#string

P2860

An evidence-based position statement on the management of irritable bowel syndrome.

Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain.

Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.

Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.

Taking a lesson from microbial diarrheagenesis in the management of chronic constipation.

Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation.

Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.

P304

1535-1543

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1Q428

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22045908

http://www.w3.org/2001/XMLSchema#string

P921

linaclotide

Linaclotide: a novel approach to the treatment of irritable bowel syndrome.

about

P2860

P2860

Linaclotide: a novel approach to the treatment of irritable bowel syndrome.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921